Monitor for imminent warrant exercise and secondary selling pressure; the low strike price makes exercise highly likely, which could weigh on the stock. Cross-check with insider activity and financing plans given low cash balance ($4M) and recent earnings miss context.
Price Chart
Executive Summary
Cadrenal Therapeutics amended the exercise price of existing warrants to purchase 571,430 shares from $16.50 to $4.50 per share, significantly below the prior price and close to the $5.12 closing price on March 31, 2026. This increases the likelihood of warrant exercise but is dilutive to existing shareholders.
Key Facts
- Amended exercise price of warrants for 571,430 shares from $16.50 to $4.50 per share
- Amendment occurred on March 31, 2026, one day after earnings release
- Stock closed at $5.12 on March 31, 2026, making the new exercise price only 12% below market
- Warrant amendment increases near-term dilution risk
- Part of a larger registration for resale of 590,001 shares
Financial Impact
Potential immediate dilution of ~25% of current shares outstanding if all amended warrants are exercised; based on 571,430 shares versus 2.3M shares outstanding as of Dec 31, 2025
Risk Factors
- Significant near-term share dilution
- Downward pressure on stock price due to anticipated selling by warrant holder post-exercise
- Perception of distress given deep in-the-money amendment shortly after earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-038010 |
| Document: 0001213900-26-038010-index-headers.html | 0001213900-26-038010 |
| Document: 0001213900-26-038010-index.html | 0001213900-26-038010 |
| Document: 0001213900-26-038010.txt | 0001213900-26-038010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $0.9723 | awaiting T+60 | — | $0.9011 (−7.32%) |
Aug 31, 2026 8w ago | 8-K | $1.75 | awaiting T+60 | — | $0.9011 (−48.51%) |
Jul 21, 2026 14w ago | 8-K | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9011 (−58.47%) |
Jul 21, 2026 14w ago | EFFECT | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9011 (−58.47%) |
Jul 1, 2026 16w ago | Press Release | $3.60 $1.12 | ▲ +68.89% | ▲ +71.94% | $0.9011 (+74.97%) |
Jun 29, 2026 17w ago | 8-K | $3.34 $1.32 | ▼ −60.48% | ▼ −64.04% | $0.9011 (−73.02%) |
Jun 18, 2026 18w ago | 8-K | $3.50 $1.06 | ▼ −69.71% | ▼ −71.61% | $0.9011 (−74.25%) |
Jun 15, 2026 19w ago | 144 | $3.04 $1.18 | ▲ +61.18% | ▲ +62.18% | $0.9011 (+70.36%) |
May 7, 2026 24w ago | Press Release | $6.02 $1.96 | ▼ −67.44% | ▼ −71.27% | $0.9011 (−85.03%) |
Apr 30, 2026 25w ago | 8-K | $6.67 $2.06 | ▼ −69.12% | ▼ −72.22% | $0.9011 (−86.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers